United Kingdom Immunotherapy Drugs Market Size, Share, and COVID-19 Impact Analysis, By Type (Monoclonal Antibodies, Vaccines, Immunomodulators, and Others), By Therapeutic Area (Cancer, Autoimmune and Inflammatory Diseases, Infectious Diseases, and Others), and United Kingdom Immunotherapy Drugs Market Insights, Industry Trend, Forecasts to 2035
Industry: HealthcareUnited Kingdom immunotherapy drugs Market Insights Forecasts to 2035
- The United Kingdom Immunotherapy Drugs Market Size was Estimated at USD 9930.22 Million in 2024
- The Market Size is Expected to Grow at a CAGR of around 10.91% from 2025 to 2035
- The United Kingdom Immunotherapy Drugs Market Size is Expected to Reach USD 31025.45 Million by 2035
Get more details on this report -
According to a research report published by Spherical Insights & Consulting, The United Kingdom Immunotherapy Drugs Market Size is anticipated to reach USD 31025.45 Million by 2035, growing at a CAGR of 10.91% from 2025 to 2035. Biotechnology technological developments and increased research expenditures are driving market growth. The need for novel immunotherapy treatments is anticipated to increase as chronic illness rates continue to climb, opening up new opportunities for medical advancements and better patient outcomes.
Market Overview
The market for UK immunotherapy medications is the area of the country's biopharmaceutical and healthcare industries that is devoted to the study, creation, manufacturing, and distribution of medications that strengthen or alter the body's immune system in order to treat illnesses, especially infectious diseases, cancer, and autoimmune conditions. Drugs used in immunotherapy include cytokine-based therapies, cancer vaccines, immune checkpoint inhibitors, monoclonal antibodies, and adoptive cell therapies (like CAR-T). This market is propelled in the UK by rising cancer rates, precision medicine breakthroughs, robust R&D facilities, and the active participation of both domestic and international pharmaceutical businesses. The use of immunotherapies by the NHS and the private sector is included, as are collaborations between academia and industry that promote clinical trials and innovation nationwide. Further, the NHS in England is the first healthcare system to provide a five-minute subcutaneous injection of nivolumab (Opdivo), which eliminates the need for drawn-out IV drips in favor of a brief, under-the-skin injection. The medicine has been modified to treat 15 distinct forms of cancer, including colorectal, lung, skin, bladder, oesophageal, kidney, and head and neck malignancies. Nivolumab, an injectable immunotherapy, is being introduced by the health service, allowing patients to receive their treatments every two weeks or every month.
Report Coverage
This research report categorizes the market for the United Kingdom immunotherapy drugs market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the United Kingdom immunotherapy drugs market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the United Kingdom immunotherapy drugs market.
United Kingdom Immunotherapy Drugs Market Report Coverage
Report Coverage | Details |
---|---|
Base Year: | 2024 |
Market Size in 2024: | USD 9930.22 Million |
Forecast Period: | 2025-2035 |
Forecast Period CAGR 2025-2035 : | 10.91% |
2035 Value Projection: | USD 31025.45 Million |
Historical Data for: | 2020-2023 |
No. of Pages: | 178 |
Tables, Charts & Figures: | 124 |
Segments covered: | By Type and By Therapeutic Area |
Companies covered:: | AstraZeneca plc, GSK, Immunocore, Barinthus (Vaccitech), Scancell, GammaDelta, Crescendo Biologics, and Others |
Pitfalls & Challenges: | COVID-19 Impact, Challenges, Future, Growth, & Analysis |
Get more details on this report -
Driving Factors
The market for United Kingdom immunotherapy drugs is driven by the rising incidence of chronic diseases, particularly cancer, and the rising demand for therapies that strengthen the immune system. Ongoing research and development initiatives are anticipated to produce more inventive treatments as the market develops, enhancing patient outcomes and increasing the range of treatment options available for individuals with chronic illnesses. This development is expected to be strengthened by immunotherapy's growing popularity over traditional therapeutic approaches. The efficiency of immunotherapy in treating a range of malignancies and autoimmune disorders, as well as the rising need for monoclonal biosimilars, are the main causes of this change. Furthermore, the market has grown substantially as a result of the existence of local and major leading biopharmaceutical companies and a well-developed healthcare infrastructure.
Restraining Factors
The market expansion could be hampered by the high treatment costs and rivalry in medication development.
Market Segmentation
The United Kingdom immunotherapy drugs market share is classified into type and therapeutic area.
- The monoclonal antibodies segment held a significant share in 2024 and is expected to grow at a notable CAGR during the forecast period.
The United Kingdom immunotherapy drugs market is segmented by type into monoclonal antibodies, vaccines, immunomodulators, and others. Among these, the monoclonal antibodies segment held a significant share in 2024 and is expected to grow at a notable CAGR during the forecast period. This is due this is most effective type of immunotherapy that cures various chronic diseases, with the higher safety of the immunotherapy, owing to the lower toxicity, resulting in minimal or no side effects. The increasing popularity of monoclonal antibodies due to their low side effects is fueling the demand for monoclonal antibodies. The government authorities are playing a crucial role in the rising adoption of monoclonal antibodies.
- The cancer segment dominated the market in 2024 and is expected to grow at a substantial CAGR during the forecast period.
The United Kingdom immunotherapy drugs market is segmented by therapeutic area into cancer, autoimmune and inflammatory diseases, infectious diseases, and others. Among these, the cancer segment dominated the market in 2024 and is expected to grow at a substantial CAGR during the forecast period. This is because of the rising incidence of cancer and the switch from chemotherapy to an alternative because of its side effects, which are two main factors propelling this category's revenue development.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom immunotherapy drugs market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
List of Key Companies
- AstraZeneca plc
- GSK
- Immunocore
- Barinthus (Vaccitech)
- Scancell
- GammaDelta
- Crescendo Biologics
- Others
Recent Developments:
- In May 2025, the UK would replace the conventional hour-long IV (intravenous) drip with a 15-minute injection of the immunotherapy medication Nivolumab to treat malignancies more quickly. Immunotherapy medications will be administered to cancer patients in the UK in a single injection for quicker treatment.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Market Segment
This study forecasts revenue at United Kingdom, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the United Kingdom immunotherapy drugs market based on the below-mentioned segments:
United Kingdom Immunotherapy Drugs Market, By Type
- Monoclonal Antibodies
- Vaccines
- Immunomodulators
- Others
United Kingdom Immunotherapy Drugs Market, By Therapeutic Area
- Cancer
- Autoimmune and Inflammatory Diseases
- Infectious Diseases
- Others
Need help to buy this report?